Research graph
References from Adverse Outcomes of Transthyretin p.V142I Carriers With Non-Amyloid Heart Failure:The SCAN-MP Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Cardiac amyloidosis due to transthyretin protein
10.1001/jama.2024.0442 · 2024 · External reference
Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review
10.1016/j.jacc.2019.04.003 · 2019 · External reference
Association of transthyretin Val122Ile variant with incident heart failure among Black individuals
10.1001/jama.2022.2896 · 2022 · External reference
Current and evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy
10.1016/j.jcmg.2023.10.010 · 2024 · External reference
Transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure
10.1001/jamacardio.2025.2948 · 2025 · External reference
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
10.1161/circulationaha.116.021612 · 2016 · External reference
Early detection of transthyretin cardiac amyloidosis using 124i-evuzamitide positron emission tomography/computed tomography
10.1016/j.jcmg.2025.01.018 · 2025 · External reference
Determinants of transthyretin levels and their association with adverse clinical outcomes among UK Biobank participants
10.1038/s41467-024-50231-1 · 2024 · External reference
